Publication:
Impact of Eculizumab on Hospitalization Rates and Relapse Treatment in Patients with Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder: Findings from the Phase 3 PREVENT Study

Simple item page
dc.contributor.authorKim, H. J.
dc.contributor.authorPittock, S. J.
dc.contributor.authorBerthele, A.
dc.contributor.authorFujihara, K.
dc.contributor.authorLevy, M.
dc.contributor.authorPalace, J.
dc.contributor.authorWingerchuk, D. M.
dc.contributor.authorIDNakashima, Ichiro/0000-0002-2612-8948
dc.date.accessioned2020-06-21T12:26:00Z
dc.date.available2020-06-21T12:26:00Z
dc.date.issued2019
dc.departmentOMÜen_US
dc.department-temp[Kim, H. J.] Natl Canc Ctr, Neurol, Goyang, South Korea -- [Pittock, S. J.] Mayo Clin, Dept Neurol, Rochester, MN USA -- [Berthele, A.] Tech Univ Munich, Klinikum Rechts Isar, Dept Neurol, Munich, Germany -- [Fujihara, K. -- Nakashima, I.] Tohoku Univ, Grad Sch Med, Dept Neurol, Sendai, Miyagi, Japan -- [Fujihara, K.] Fukushima Med Univ, Sch Med, Dept Multiple Sclerosis Therapeut, Fukushima, Japan -- [Fujihara, K.] Southern TOHOKU Res Inst Neurosci STRINS, MS & NMO Ctr, Koriyama, Fukushima, Japanen_US
dc.description35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS -- SEP 11-13, 2019 -- Stockholm, SWEDENen_US
dc.description.abstract…en_US
dc.description.sponsorshipEuropean Comm Treatment & Res Multiple Sclerosis, Congrex Switzerland Ltden_US
dc.description.sponsorshipAlexion PharmaceuticalsFukuda Foundation for Medical TechnologyKayamori FoundationKayamori Foundation of Informational Science AdvancementSENSHIN Medical Research FoundationSasagawa Scientific Research GrantMukai Science and Technology Foundationen_US
dc.description.sponsorshipThis trial was supported by Alexion Pharmaceuticals. Dr Berthele reports compensations for clinical trials received by his institution from Alexion Pharmaceuticals, Biogen, Novartis Pharmaceuticals, Roche, Sanofi Genzyme and Teva Pharmaceuticals, and personal fees and non-financial support from Bayer Healthcare, Biogen, Merck Serono, Mylan, Novartis Pharmaceuticals, Roche and Sanofi Genzyme.; Dr Palace is partly funded by highly specialized services to run a national congenital myasthenia service and a neuromyelitis service. She has received support for scientific meetings and fees for advisory work from Abide, Alexion, ARGENX, Bayer Schering, Biogen Idec, Chugai Pharma, EuroImmun, Genzyme, MedDay, MedImmune, Merck Serono, Novartis, Roche and Teva, and grants from Abide, Bayer Schering, Biogen Idec, Merck Serono, Novartis and Teva. She has received grants from EDEN, GMSI, the Guthy-Jackson Charitable Foundation, the John Fell Fund, MRC, the MS Society, NIHR and Oxford Health Services Research Committee for research studies.; Dr Wingerchuk reports grants from Alexion Pharmaceuticals during the conduct of the study; and personal fees from Biogen, BrainStorm Therapeutics, Caladrius, Celgene, MedImmune, Novartis and ONO Pharmaceutical.en_US
dc.identifier.endpage289en_US
dc.identifier.issn1352-4585
dc.identifier.issn1477-0970
dc.identifier.startpage288en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12712/10620
dc.identifier.volume25en_US
dc.identifier.wosWOS:000485303101160
dc.language.isoenen_US
dc.publisherSAGE Publications Ltden_US
dc.relation.journalMultiple Sclerosis Journalen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleImpact of Eculizumab on Hospitalization Rates and Relapse Treatment in Patients with Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder: Findings from the Phase 3 PREVENT Studyen_US
dc.typeConference Objecten_US
dspace.entity.typePublication

Files

Collections

WoS İndeksli Yayınlar Koleksiyonu